Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy* Article Swipe
Shaojie Xu
,
Yiming Feng
,
Xingyin Li
,
Zaozao Huang
,
Hewei Li
,
Ganxin Wang
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1007/s10330-021-0547-7
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1007/s10330-021-0547-7
Objective Antibodies targeting programmed cell death protein 1 (PD-1) have become the mainstay of treatment for chemotherapy-refractory gastric cancer, characterized by high levels of programmed cell death ligand-1 (PDL-1) expression. However, the routine clinical implementation of PDL-1 testing is currently limited by the lack of robust detection methods. In this regard, the role of plasma γ-glutamyl transpeptidase (GGT), an N-terminal nucleophilic hydrolase, as an independent predictor of the efficacy of anti-PD-1 therapy remains unknown. In this study, we aimed to assessed the prognostic role of changes in plasma GGT levels (6 weeks vs. baseline) in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy. Methods We retrospectively analyzed data from 57 patients with gastric cancer treated with anti-PD-1 antibodies (camrelizumab, sintilimab, nivolumab, tislelizumab, and toripalimab) at the Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, from July 2018 to February 2021. Results We found that after 6 weeks of treatment, there were significant differences between responders and non-responders with respect to plasma GGT levels ( P < 0.001). Multivariate logistic regression analysis revealed that the continuous value of the 6-week difference in GGT levels (OR = 1.437, 95% CI = 1.116-1.849, P = 0.005) and 6-week difference in GGT ≥ 0 or < 0 (OR = 53.675, 95% CI = 6.379-451.669, P < 0.001) were independent predictors of disease control. Survival analysis indicated that a reduction in plasma GGT6 levels during treatment was significantly associated with a favorable progression-free survival (PFS) and overall survival ( P < 0.001). Consistently, univariate and multivariate Cox regression analyses revealed that a reduction in plasma GGT6 levels during treatment was an independent predictor of PFS (HR = 1.033, 95% CI = 1.013-1.053, P = 0.001). Conclusion Alterations in plasma GGT levels during treatment can be used as a predictor of disease progression and survival in patients with advanced gastric cancer undergoing treatment with anti-PD-1 antibodies.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1007/s10330-021-0547-7
- http://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022
- OA Status
- diamond
- References
- 21
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4380589370
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4380589370Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1007/s10330-021-0547-7Digital Object Identifier
- Title
-
Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy*Work title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-06-01Full publication date if available
- Authors
-
Shaojie Xu, Yiming Feng, Xingyin Li, Zaozao Huang, Hewei Li, Ganxin WangList of authors in order
- Landing page
-
https://doi.org/10.1007/s10330-021-0547-7Publisher landing page
- PDF URL
-
https://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022Direct OA link when available
- Concepts
-
Medicine, Internal medicine, Cancer, Gastroenterology, Immunotherapy, Antibody, Oncology, Nivolumab, Chemotherapy, ImmunologyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
21Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4380589370 |
|---|---|
| doi | https://doi.org/10.1007/s10330-021-0547-7 |
| ids.doi | https://doi.org/10.1007/s10330-021-0547-7 |
| ids.openalex | https://openalex.org/W4380589370 |
| fwci | 0.0 |
| type | article |
| title | Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy* |
| biblio.issue | 3 |
| biblio.volume | 8 |
| biblio.last_page | 114 |
| biblio.first_page | 109 |
| topics[0].id | https://openalex.org/T12996 |
| topics[0].field.id | https://openalex.org/fields/13 |
| topics[0].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[0].score | 0.9987000226974487 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/1305 |
| topics[0].subfield.display_name | Biotechnology |
| topics[0].display_name | Cancer Research and Treatments |
| topics[1].id | https://openalex.org/T10158 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9979000091552734 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cancer Immunotherapy and Biomarkers |
| topics[2].id | https://openalex.org/T10231 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9976000189781189 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Pancreatic and Hepatic Oncology Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.7996159195899963 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C126322002 |
| concepts[1].level | 1 |
| concepts[1].score | 0.706717848777771 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[1].display_name | Internal medicine |
| concepts[2].id | https://openalex.org/C121608353 |
| concepts[2].level | 2 |
| concepts[2].score | 0.6162208914756775 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[2].display_name | Cancer |
| concepts[3].id | https://openalex.org/C90924648 |
| concepts[3].level | 1 |
| concepts[3].score | 0.611068069934845 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[3].display_name | Gastroenterology |
| concepts[4].id | https://openalex.org/C2777701055 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5595133304595947 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[4].display_name | Immunotherapy |
| concepts[5].id | https://openalex.org/C159654299 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5071611404418945 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[5].display_name | Antibody |
| concepts[6].id | https://openalex.org/C143998085 |
| concepts[6].level | 1 |
| concepts[6].score | 0.45330604910850525 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[6].display_name | Oncology |
| concepts[7].id | https://openalex.org/C2780030458 |
| concepts[7].level | 4 |
| concepts[7].score | 0.45119568705558777 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7041828 |
| concepts[7].display_name | Nivolumab |
| concepts[8].id | https://openalex.org/C2776694085 |
| concepts[8].level | 2 |
| concepts[8].score | 0.42069488763809204 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[8].display_name | Chemotherapy |
| concepts[9].id | https://openalex.org/C203014093 |
| concepts[9].level | 1 |
| concepts[9].score | 0.3431355953216553 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[9].display_name | Immunology |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.7996159195899963 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/internal-medicine |
| keywords[1].score | 0.706717848777771 |
| keywords[1].display_name | Internal medicine |
| keywords[2].id | https://openalex.org/keywords/cancer |
| keywords[2].score | 0.6162208914756775 |
| keywords[2].display_name | Cancer |
| keywords[3].id | https://openalex.org/keywords/gastroenterology |
| keywords[3].score | 0.611068069934845 |
| keywords[3].display_name | Gastroenterology |
| keywords[4].id | https://openalex.org/keywords/immunotherapy |
| keywords[4].score | 0.5595133304595947 |
| keywords[4].display_name | Immunotherapy |
| keywords[5].id | https://openalex.org/keywords/antibody |
| keywords[5].score | 0.5071611404418945 |
| keywords[5].display_name | Antibody |
| keywords[6].id | https://openalex.org/keywords/oncology |
| keywords[6].score | 0.45330604910850525 |
| keywords[6].display_name | Oncology |
| keywords[7].id | https://openalex.org/keywords/nivolumab |
| keywords[7].score | 0.45119568705558777 |
| keywords[7].display_name | Nivolumab |
| keywords[8].id | https://openalex.org/keywords/chemotherapy |
| keywords[8].score | 0.42069488763809204 |
| keywords[8].display_name | Chemotherapy |
| keywords[9].id | https://openalex.org/keywords/immunology |
| keywords[9].score | 0.3431355953216553 |
| keywords[9].display_name | Immunology |
| language | en |
| locations[0].id | doi:10.1007/s10330-021-0547-7 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4387290313 |
| locations[0].source.issn | 2095-9621 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2095-9621 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Oncology and Translational Medicine |
| locations[0].source.host_organization | |
| locations[0].source.host_organization_name | |
| locations[0].source.host_organization_lineage | |
| locations[0].license | |
| locations[0].pdf_url | http://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Oncology and Translational Medicine |
| locations[0].landing_page_url | https://doi.org/10.1007/s10330-021-0547-7 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5101204460 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Shaojie Xu |
| authorships[0].countries | CN |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I47720641 |
| authorships[0].affiliations[0].raw_affiliation_string | First Clinical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[0].institutions[0].id | https://openalex.org/I47720641 |
| authorships[0].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[0].institutions[0].country_code | CN |
| authorships[0].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Shaojie Xu |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | First Clinical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[1].author.id | https://openalex.org/A5039245850 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-9693-3686 |
| authorships[1].author.display_name | Yiming Feng |
| authorships[1].countries | CN, HK |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1318643470, https://openalex.org/I47720641 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[1].institutions[0].id | https://openalex.org/I47720641 |
| authorships[1].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[1].institutions[0].country_code | CN |
| authorships[1].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[1].institutions[1].id | https://openalex.org/I1318643470 |
| authorships[1].institutions[1].ror | https://ror.org/01j7r2734 |
| authorships[1].institutions[1].type | healthcare |
| authorships[1].institutions[1].lineage | https://openalex.org/I1318643470 |
| authorships[1].institutions[1].country_code | HK |
| authorships[1].institutions[1].display_name | Union Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Yiming Feng |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[2].author.id | https://openalex.org/A5055031739 |
| authorships[2].author.orcid | https://orcid.org/0009-0004-9232-6987 |
| authorships[2].author.display_name | Xingyin Li |
| authorships[2].countries | CN |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I47720641 |
| authorships[2].affiliations[0].raw_affiliation_string | First Clinical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[2].institutions[0].id | https://openalex.org/I47720641 |
| authorships[2].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[2].institutions[0].country_code | CN |
| authorships[2].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Xingyin Li |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | First Clinical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[3].author.id | https://openalex.org/A5014789461 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Zaozao Huang |
| authorships[3].countries | CN |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I47720641 |
| authorships[3].affiliations[0].raw_affiliation_string | Yangchunhu Community Hospital, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China |
| authorships[3].institutions[0].id | https://openalex.org/I47720641 |
| authorships[3].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[3].institutions[0].country_code | CN |
| authorships[3].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Zaozao Huang |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Yangchunhu Community Hospital, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China |
| authorships[4].author.id | https://openalex.org/A5103176020 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Hewei Li |
| authorships[4].countries | CN |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I47720641 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Orthopedics, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China |
| authorships[4].institutions[0].id | https://openalex.org/I47720641 |
| authorships[4].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[4].institutions[0].country_code | CN |
| authorships[4].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Hewei Li |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Orthopedics, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430077, China |
| authorships[5].author.id | https://openalex.org/A5114057802 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Ganxin Wang |
| authorships[5].countries | CN, HK |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I1318643470, https://openalex.org/I47720641 |
| authorships[5].affiliations[0].raw_affiliation_string | Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| authorships[5].institutions[0].id | https://openalex.org/I47720641 |
| authorships[5].institutions[0].ror | https://ror.org/00p991c53 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I47720641 |
| authorships[5].institutions[0].country_code | CN |
| authorships[5].institutions[0].display_name | Huazhong University of Science and Technology |
| authorships[5].institutions[1].id | https://openalex.org/I1318643470 |
| authorships[5].institutions[1].ror | https://ror.org/01j7r2734 |
| authorships[5].institutions[1].type | healthcare |
| authorships[5].institutions[1].lineage | https://openalex.org/I1318643470 |
| authorships[5].institutions[1].country_code | HK |
| authorships[5].institutions[1].display_name | Union Hospital |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Ganxin Wang |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | http://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022 |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Prognostic role of plasma levels of γ-glutamyl transpeptidase in patients with advanced gastric cancer treated with anti-PD-1 immunotherapy* |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T12996 |
| primary_topic.field.id | https://openalex.org/fields/13 |
| primary_topic.field.display_name | Biochemistry, Genetics and Molecular Biology |
| primary_topic.score | 0.9987000226974487 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/1305 |
| primary_topic.subfield.display_name | Biotechnology |
| primary_topic.display_name | Cancer Research and Treatments |
| related_works | https://openalex.org/W2976744492, https://openalex.org/W2898986397, https://openalex.org/W3021851930, https://openalex.org/W2981652925, https://openalex.org/W2890849069, https://openalex.org/W2800160190, https://openalex.org/W4206636567, https://openalex.org/W2989731915, https://openalex.org/W2947988614, https://openalex.org/W2478002927 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1007/s10330-021-0547-7 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4387290313 |
| best_oa_location.source.issn | 2095-9621 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2095-9621 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Oncology and Translational Medicine |
| best_oa_location.source.host_organization | |
| best_oa_location.source.host_organization_name | |
| best_oa_location.source.host_organization_lineage | |
| best_oa_location.license | |
| best_oa_location.pdf_url | http://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Oncology and Translational Medicine |
| best_oa_location.landing_page_url | https://doi.org/10.1007/s10330-021-0547-7 |
| primary_location.id | doi:10.1007/s10330-021-0547-7 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4387290313 |
| primary_location.source.issn | 2095-9621 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2095-9621 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Oncology and Translational Medicine |
| primary_location.source.host_organization | |
| primary_location.source.host_organization_name | |
| primary_location.source.host_organization_lineage | |
| primary_location.license | |
| primary_location.pdf_url | http://otm.tjh.com.cn/ch/reader/create_pdf.aspx?file_no=OTM210547&flag=1&journal_id=zdlczlzz&year_id=2022 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Oncology and Translational Medicine |
| primary_location.landing_page_url | https://doi.org/10.1007/s10330-021-0547-7 |
| publication_date | 2022-06-01 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W2763064222, https://openalex.org/W2793364080, https://openalex.org/W2948169107, https://openalex.org/W6776905446, https://openalex.org/W1951830410, https://openalex.org/W1529811985, https://openalex.org/W6680932049, https://openalex.org/W2590710686, https://openalex.org/W3165695406, https://openalex.org/W2109002581, https://openalex.org/W1914193268, https://openalex.org/W3097129845, https://openalex.org/W2106054392, https://openalex.org/W3159809552, https://openalex.org/W3007389146, https://openalex.org/W2009072976, https://openalex.org/W2992101590, https://openalex.org/W6777599557, https://openalex.org/W3025813234, https://openalex.org/W2140521989, https://openalex.org/W3024255047 |
| referenced_works_count | 21 |
| abstract_inverted_index.( | 170, 250 |
| abstract_inverted_index.0 | 206, 209 |
| abstract_inverted_index.1 | 8 |
| abstract_inverted_index.6 | 152 |
| abstract_inverted_index.= | 191, 195, 198, 211, 215, 278, 282, 285 |
| abstract_inverted_index.P | 171, 197, 217, 251, 284 |
| abstract_inverted_index.a | 230, 242, 263, 299 |
| abstract_inverted_index.(6 | 91 |
| abstract_inverted_index.57 | 111 |
| abstract_inverted_index.CI | 194, 214, 281 |
| abstract_inverted_index.In | 49, 75 |
| abstract_inverted_index.We | 106, 148 |
| abstract_inverted_index.an | 59, 64, 272 |
| abstract_inverted_index.as | 63, 298 |
| abstract_inverted_index.at | 126 |
| abstract_inverted_index.be | 296 |
| abstract_inverted_index.by | 21, 42 |
| abstract_inverted_index.in | 87, 95, 187, 203, 232, 265, 289, 306 |
| abstract_inverted_index.is | 39 |
| abstract_inverted_index.of | 14, 24, 36, 45, 54, 67, 70, 85, 135, 154, 183, 223, 275, 301 |
| abstract_inverted_index.or | 207 |
| abstract_inverted_index.to | 80, 144, 166 |
| abstract_inverted_index.we | 78 |
| abstract_inverted_index.(HR | 277 |
| abstract_inverted_index.(OR | 190, 210 |
| abstract_inverted_index.95% | 193, 213, 280 |
| abstract_inverted_index.Cox | 258 |
| abstract_inverted_index.GGT | 89, 168, 188, 204, 291 |
| abstract_inverted_index.PFS | 276 |
| abstract_inverted_index.and | 124, 137, 162, 200, 247, 256, 304 |
| abstract_inverted_index.can | 295 |
| abstract_inverted_index.for | 16 |
| abstract_inverted_index.the | 12, 32, 43, 52, 68, 82, 127, 180, 184 |
| abstract_inverted_index.vs. | 93 |
| abstract_inverted_index.was | 238, 271 |
| abstract_inverted_index.≥ | 205 |
| abstract_inverted_index.< | 172, 208, 218, 252 |
| abstract_inverted_index.2018 | 143 |
| abstract_inverted_index.GGT6 | 234, 267 |
| abstract_inverted_index.July | 142 |
| abstract_inverted_index.cell | 5, 26 |
| abstract_inverted_index.data | 109 |
| abstract_inverted_index.from | 110, 141 |
| abstract_inverted_index.have | 10 |
| abstract_inverted_index.high | 22 |
| abstract_inverted_index.lack | 44 |
| abstract_inverted_index.role | 53, 84 |
| abstract_inverted_index.that | 150, 179, 229, 262 |
| abstract_inverted_index.this | 50, 76 |
| abstract_inverted_index.used | 297 |
| abstract_inverted_index.were | 157, 220 |
| abstract_inverted_index.with | 97, 102, 113, 117, 164, 241, 308, 314 |
| abstract_inverted_index.(PFS) | 246 |
| abstract_inverted_index.2021. | 146 |
| abstract_inverted_index.PDL-1 | 37 |
| abstract_inverted_index.Union | 128 |
| abstract_inverted_index.after | 151 |
| abstract_inverted_index.aimed | 79 |
| abstract_inverted_index.death | 6, 27 |
| abstract_inverted_index.found | 149 |
| abstract_inverted_index.there | 156 |
| abstract_inverted_index.value | 182 |
| abstract_inverted_index.weeks | 92, 153 |
| abstract_inverted_index.(GGT), | 58 |
| abstract_inverted_index.(PD-1) | 9 |
| abstract_inverted_index.0.001) | 219 |
| abstract_inverted_index.0.005) | 199 |
| abstract_inverted_index.1.033, | 279 |
| abstract_inverted_index.1.437, | 192 |
| abstract_inverted_index.6-week | 185, 201 |
| abstract_inverted_index.China, | 140 |
| abstract_inverted_index.Tongji | 130 |
| abstract_inverted_index.Wuhan, | 139 |
| abstract_inverted_index.become | 11 |
| abstract_inverted_index.cancer | 100, 115, 311 |
| abstract_inverted_index.during | 236, 269, 293 |
| abstract_inverted_index.levels | 23, 90, 169, 189, 235, 268, 292 |
| abstract_inverted_index.plasma | 55, 88, 167, 233, 266, 290 |
| abstract_inverted_index.robust | 46 |
| abstract_inverted_index.study, | 77 |
| abstract_inverted_index.(PDL-1) | 29 |
| abstract_inverted_index.0.001). | 173, 253, 286 |
| abstract_inverted_index.53.675, | 212 |
| abstract_inverted_index.Medical | 131 |
| abstract_inverted_index.Methods | 105 |
| abstract_inverted_index.Results | 147 |
| abstract_inverted_index.Science | 136 |
| abstract_inverted_index.between | 160 |
| abstract_inverted_index.cancer, | 19 |
| abstract_inverted_index.changes | 86 |
| abstract_inverted_index.disease | 224, 302 |
| abstract_inverted_index.gastric | 18, 99, 114, 310 |
| abstract_inverted_index.limited | 41 |
| abstract_inverted_index.overall | 248 |
| abstract_inverted_index.protein | 7 |
| abstract_inverted_index.regard, | 51 |
| abstract_inverted_index.remains | 73 |
| abstract_inverted_index.respect | 165 |
| abstract_inverted_index.routine | 33 |
| abstract_inverted_index.testing | 38 |
| abstract_inverted_index.therapy | 72 |
| abstract_inverted_index.treated | 101, 116 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.College, | 132 |
| abstract_inverted_index.February | 145 |
| abstract_inverted_index.However, | 31 |
| abstract_inverted_index.Huazhong | 133 |
| abstract_inverted_index.Survival | 226 |
| abstract_inverted_index.advanced | 98, 309 |
| abstract_inverted_index.analyses | 260 |
| abstract_inverted_index.analysis | 177, 227 |
| abstract_inverted_index.analyzed | 108 |
| abstract_inverted_index.assessed | 81 |
| abstract_inverted_index.clinical | 34 |
| abstract_inverted_index.control. | 225 |
| abstract_inverted_index.efficacy | 69 |
| abstract_inverted_index.ligand-1 | 28 |
| abstract_inverted_index.logistic | 175 |
| abstract_inverted_index.mainstay | 13 |
| abstract_inverted_index.methods. | 48 |
| abstract_inverted_index.patients | 96, 112, 307 |
| abstract_inverted_index.revealed | 178, 261 |
| abstract_inverted_index.survival | 245, 249, 305 |
| abstract_inverted_index.unknown. | 74 |
| abstract_inverted_index.Hospital, | 129 |
| abstract_inverted_index.Objective | 1 |
| abstract_inverted_index.anti-PD-1 | 71, 103, 118, 315 |
| abstract_inverted_index.baseline) | 94 |
| abstract_inverted_index.currently | 40 |
| abstract_inverted_index.detection | 47 |
| abstract_inverted_index.favorable | 243 |
| abstract_inverted_index.indicated | 228 |
| abstract_inverted_index.predictor | 66, 274, 300 |
| abstract_inverted_index.reduction | 231, 264 |
| abstract_inverted_index.targeting | 3 |
| abstract_inverted_index.treatment | 15, 237, 270, 294, 313 |
| abstract_inverted_index.Antibodies | 2 |
| abstract_inverted_index.Conclusion | 287 |
| abstract_inverted_index.N-terminal | 60 |
| abstract_inverted_index.University | 134 |
| abstract_inverted_index.antibodies | 119 |
| abstract_inverted_index.associated | 240 |
| abstract_inverted_index.continuous | 181 |
| abstract_inverted_index.difference | 186, 202 |
| abstract_inverted_index.hydrolase, | 62 |
| abstract_inverted_index.nivolumab, | 122 |
| abstract_inverted_index.predictors | 222 |
| abstract_inverted_index.prognostic | 83 |
| abstract_inverted_index.programmed | 4, 25 |
| abstract_inverted_index.regression | 176, 259 |
| abstract_inverted_index.responders | 161 |
| abstract_inverted_index.treatment, | 155 |
| abstract_inverted_index.undergoing | 312 |
| abstract_inverted_index.univariate | 255 |
| abstract_inverted_index.Alterations | 288 |
| abstract_inverted_index.Technology, | 138 |
| abstract_inverted_index.antibodies. | 316 |
| abstract_inverted_index.differences | 159 |
| abstract_inverted_index.expression. | 30 |
| abstract_inverted_index.independent | 65, 221, 273 |
| abstract_inverted_index.progression | 303 |
| abstract_inverted_index.significant | 158 |
| abstract_inverted_index.sintilimab, | 121 |
| abstract_inverted_index.γ-glutamyl | 56 |
| abstract_inverted_index.1.013-1.053, | 283 |
| abstract_inverted_index.1.116-1.849, | 196 |
| abstract_inverted_index.Multivariate | 174 |
| abstract_inverted_index.multivariate | 257 |
| abstract_inverted_index.nucleophilic | 61 |
| abstract_inverted_index.toripalimab) | 125 |
| abstract_inverted_index.Consistently, | 254 |
| abstract_inverted_index.characterized | 20 |
| abstract_inverted_index.significantly | 239 |
| abstract_inverted_index.tislelizumab, | 123 |
| abstract_inverted_index.(camrelizumab, | 120 |
| abstract_inverted_index.6.379-451.669, | 216 |
| abstract_inverted_index.immunotherapy. | 104 |
| abstract_inverted_index.implementation | 35 |
| abstract_inverted_index.non-responders | 163 |
| abstract_inverted_index.transpeptidase | 57 |
| abstract_inverted_index.retrospectively | 107 |
| abstract_inverted_index.progression-free | 244 |
| abstract_inverted_index.chemotherapy-refractory | 17 |
| cited_by_percentile_year | |
| countries_distinct_count | 2 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8299999833106995 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.22091993 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |